ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
核心洞察
ALZpath has entered a global licensing agreement with Abbott (搜索) to incorporate its proprietary pTau217 (搜索) antibody into an in vitro diagnostic test for Alzheimer's disease (搜索) on Abbott's Alinity ci-series systems.
The ALZpath pTau217 (搜索) antibody is backed by more than 200 peer-reviewed publications across 18 countries and has been selected by seven major diagnostic companies for assay development.
Blood-based pTau217 (搜索) testing offers a scalable, non-invasive alternative to costly PET imaging and cerebrospinal fluid analysis, potentially enabling earlier Alzheimer's diagnosis in routine care settings.
ALZpath Inc. (搜索), a leader in blood test-based diagnostic solutions for Alzheimer's disease (搜索), announced on June 24, 2026, a global licensing agreement with Abbott (搜索) to incorporate ALZpath's proprietary phosphorylated Tau 217 (pTau217 (搜索)) antibody into the development of an in vitro diagnostic (IVD) test for Alzheimer's disease. The test would be designed for use on Abbott's Alinity ci-series systems, which represents one of the largest install bases of immunoassay instruments worldwide.
The agreement positions ALZpath's antibody as a foundational component of the emerging pTau217 (搜索) IVD market and marks a significant step toward making blood-based Alzheimer's testing accessible at a global scale.
Clinical Validation and Scientific Foundation
ALZpath's pTau217 (搜索) antibody is among the most clinically validated biomarkers for detecting Alzheimer's disease (搜索) pathology. Since its launch in 2023, the antibody has been featured in 219 peer-reviewed research publications, including 205 original research articles that have generated hundreds of thousands of biomarker measurements worldwide. The antibody has also been presented in 157 posters and presentations at international scientific conferences.
"This agreement further strengthens ALZpath's leadership in blood-based Alzheimer's testing and reinforces our position as the foundational component supporting the overwhelming majority of the pTau217 (搜索) IVD market," said Mike Banville, CEO of ALZpath. "As blood-based biomarkers become central to how Alzheimer's disease (搜索) is detected and managed, partnering with a global healthcare leader like Abbott (搜索) can enable high-performance testing to reach clinicians and patients around the world at scale."
Addressing Unmet Diagnostic Needs
As disease-modifying therapies for Alzheimer's disease (搜索) continue to expand, accessible diagnostics are essential for earlier patient identification. ALZpath's pTau217 (搜索) antibody offers a scalable alternative to positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) analysis, both of which are costly, invasive, and difficult to deploy at scale. Blood-based biomarkers may also play a role in monitoring disease progression and treatment response in routine clinical practice.
"Abbott (搜索) has spent more than a decade advancing brain health science to give clinicians earlier, clearer answers," said John Frels, vice president of research and development in Abbott's Core Diagnostics business. "Collaborations like this are accelerating the next era of Alzheimer's disease (搜索) research, clinical trials for therapies and ultimately patient care."
Broad Diagnostic Partner Ecosystem
The Abbott (搜索) agreement adds to ALZpath's growing network of diagnostic partners. The pTau217 (搜索) antibody has been selected by Abbott, Beckman-Coulter Diagnostics (搜索), Roche, Siemens Healthineers (搜索), Alamar Biosciences (搜索), Bio-Techne (搜索), and Quanterix (搜索) for the development of research and clinical pTau217 assays.
AAIC 2026 Presence Underscores Scientific Confidence
The breadth of clinical impact was further demonstrated at the Alzheimer's Association International Conference (AAIC) held July 12–15, 2026, in London, where data highlighting the ALZpath pTau217 (搜索) antibody was featured in 86 scientific presentations from 56 leading academic, clinical, and industry organizations.
"The breadth of research being presented at AAIC reflects the growing scientific confidence in the ALZpath pTau217 (搜索) antibody and its central role as a diagnostic cornerstone for Alzheimer's disease (搜索) research and clinical applications," Banville said.
Notable presentations included Roche's evaluation of a future in vitro diagnostic pTau217 (搜索) plasma assay for detecting amyloid pathology in primary and secondary care settings, Bio-Techne (搜索)'s data on ultrasensitive detection of blood-based biomarkers using the automated Ella system, and research from Harvard Medical School on the prognostic value of blood-based p-tau217 levels for progression to cognitive impairment.
ALZpath's innovations have earned multiple industry honors, including Time Magazine Best Inventions (2024), Fast Company Most Innovative Companies (2025), and BioTech Breakthrough "Diagnostic Innovation of the Year" (2025).